Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen in the results of a large phase 3 clinical trial reported today at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium in San Francisco, California.
The biggest private biotech investments in May 2023
The companies ElevateBio, ReNAgade Therapeutics and Carmot Therapeutics bagged the biggest biotech investments in May 2023. Around the world, biomanufacturing and oncology players attracted the